Financials data is unavailable for this security.
View more
Year on year Tatva Chintan Pharma Chem Ltd 's revenues fell -7.11% from 4.24bn to 3.94bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 454.87m to 303.54m, a -33.27% decrease.
| Gross margin | 54.98% |
|---|---|
| Net profit margin | 6.78% |
| Operating margin | 8.63% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Tatva Chintan Pharma Chem Ltd increased its cash reserves by 29.01%, or 79.39m. The company earned 980.44m from its operations for a Cash Flow Margin of 24.92%. In addition the company generated 305.19m cash from financing while 1.21bn was spent on investing.
| Cash flow per share | 22.55 |
|---|---|
| Price/Cash flow per share | 44.14 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -35.38%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.08% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 17.95% |
| EPS growth(5 years) | 7.43 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -44.83 |
More ▼
